Diagnosis and Treatment for Gastrointestinal Tract Stromal Tumors of Small Intestine

荣维淇,王黎明,吴凡,崔修铮,刘立国,苗成利,吴健雄
DOI: https://doi.org/10.13267/j.cnki.syzlzz.2011.02.010
2011-01-01
Abstract:Objective To review the diagnosis,treatment and prognosis of gastrointestinal stromal tumors(GIST) of the small intestine.Methods The clinicopathological and follow-up data of 25 patients with GIST of the small intestine admitted to Cancer Hospital during March 1999 to May 2006 were analyzed retrospectively.Results The pathological examination showed malignant lesions in 23 cases(92.0%),junctional lesions in 2 cases(8.0%).The clinical signs included gastrointestinal bleeding,epigastric pain and mass in abdomen.Twenty-five patients underwent operation,including radical operations in 23 cases and palliative operations in 2 cases.The positive rate of CDll7 was 94.4%(17/18) and that of CD34 was 50.0%(10/20).There was no surgical mortality.The average follow-up time was 8 years and 18 cases had recurrence of metastasis.All cases received therapy of imatinib after operation.The median period of disease-free survival(DFS) in patients with short-term imatinib therapy was(15±3)months;that with long-term therapy was(52±3)months;the overall DFS time was(35±13)months.The median survival period for cases of recurrence and metastasis with no therapy was(6±0.3)months;that for cases with imatinib therapy was(23±10)months;for cases with imatinib therapy plus operation was(51±11)months;the overall median survival period of the cases with recurrence and metastasis was(12±13)months.The 1-,3-,5-year median survival rates of DFS with short-term and long-term of imatinib therapy were 57.0%,21.0%,21.0% and 100.0%,82.0%,36.0%,respectively.The 0.5-,1-,3-,5-year median survival rates for cases of recurrence and metastasis with no therapy,imatinib therapy and imatinib therapy plus operation were 14.0%,0.0%,0.0%,0.0%;64.0%,51.0%,0.0%,0.0% and 88.0%,83.0%,76.0%,21.0%,respectively.Conclusions The diagnosis of GIST of small intestine relies on clinical,histopathological and immunohistochemical examinations because of lacking specific clinical manifestations.CD117 and CD34 are important markers for the diagnosis of GIST of small intestine.The curative-intent operation and molecular target therapy are important in treatment of GIST.The active therapy including the molecular target therapy and reoperation will prolong the survival of patients with GIST of small intestine who suffered from postoperative recurrence and metastasis.
What problem does this paper attempt to address?